Diagnostic value of 18F-FDG-PET or PET-CT in recurrent cervical cancer: a systematic review and meta-analysis

被引：47
作者：
Chu, Yanxia [1 ]
Zheng, Ai [1 ]
Wang, Fei [2 ]
Lin, Wei [1 ]
Yang, Xiaoyun [1 ]
Han, Ling [1 ]
Chen, Yali [1 ]
Bai, Liping [1 ]
机构：
[1] Sichuan Univ, W China Univ Hosp 2, Dept Obstet & Gynecol, Chengdu 610041, Sichuan, Peoples R China
[2] Peoples Hosp Shanxi Prov, Dept Obstet & Gynecol, Xian 710068, Shanxi, Peoples R China
来源：
NUCLEAR MEDICINE COMMUNICATIONS | 2014年 / 35卷 / 02期
关键词：
cervix; meta-analysis; recurrence; tomography; SQUAMOUS-CELL CARCINOMA; POSITRON-EMISSION-TOMOGRAPHY; UTERINE CERVIX; SCC ANTIGEN; FDG-PET/CT; FOLLOW-UP; IMPACT; THERAPY; F-18-FLUORODEOXYGLUCOSE; MALIGNANCIES;
D O I：
10.1097/MNM.0000000000000026
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
ObjectivesAccurate detection of recurrent cervical cancer remains a clinical difficulty. This study aims to assess the diagnostic value of PET or PET-computed tomography (PET-CT) using F-18-fluorodeoxyglucose (F-18-FDG) in recurrent cervical cancer using a meta-analysis.Study designAll published studies in English evaluating the diagnostic value of PET or PET-CT in detecting recurrent cervical cancer were collected. The methodological quality of the included studies was evaluated. Pooled sensitivity, specificity, diagnostic odds ratio, and summary receiver-operating characteristic curves were obtained using statistical software. Twenty studies were included in the meta-analysis.ResultsThe meta-analysis showed that the pooled sensitivity and specificity of PET and PET-CT to detect distant metastasis in recurrent cervical cancer were 0.87 [95% confidence interval (CI): 0.80-0.92] and 0.97 (95% CI: 0.96-0.98), respectively. The pooled sensitivity and specificity for local regional recurrence were 0.82 (95% CI: 0.72-0.90) and 0.98 (95% CI: 0.96-0.99), respectively.Conclusion(18)F-FDG-PET and PET-CT are valuable methods for the assessment of recurrent cervical cancer.
引用
收藏
页码：144 / 150
页数：7
相关论文
共 36 条
[1]   The role of hybrid PET/CT in the evaluation of patients with cervical cancer [J].
Amit, A ;
Beck, D ;
Lowenstein, L ;
Lavie, O ;
Bar Shalom, R ;
Kedar, Z ;
Israel, O .
GYNECOLOGIC ONCOLOGY, 2006, 100 (01) :65-69
[2]   Contribution of whole-body 18FDG PET imaging in the management of cervical cancer [J].
Belhocine, T ;
Thille, A ;
Fridman, V ;
Albert, A ;
Seidel, L ;
Nickers, P ;
Kridelka, F ;
Rigo, P .
GYNECOLOGIC ONCOLOGY, 2002, 87 (01) :90-97
[3]  
Borras G, 1991, EUR J GYNAECOL ONCOL, V13, P414
[4]  
Cetina L, 2011, REV INVEST CLIN, V63, P227
[5]   Positron emission tomography for unexplained elevation of serum squamous cell carcinoma antigen levels during follow-up for patients with cervical malignancies - A phase II study [J].
Chang, TC ;
Law, KS ;
Hong, JH ;
Lai, CH ;
Ng, KK ;
Hsueh, S ;
See, LC ;
Chang, YC ;
Tsai, CS ;
Chou, HH ;
Huang, KG ;
Liou, JD ;
Lin, CT ;
Chao, A ;
Chen, MY ;
Wu, TI ;
Ma, SY ;
Yen, TC .
CANCER, 2004, 101 (01) :164-171
[6]   Clinical impact of integrated PET/CT on the management of suspected cervical cancer recurrence [J].
Chung, Hyun Hoon ;
Jo, Hoenil ;
Kang, Won Jun ;
Kim, Jae Weon ;
Park, Noh-Hyun ;
Song, Yong-Sang ;
Chung, June-Key ;
Kang, Soon-Beom ;
Lee, Hyo-Pyo .
GYNECOLOGIC ONCOLOGY, 2007, 104 (03) :529-534
[7]  
CUNNINGHAM JJ, 1974, RADIOL CLIN N AM, V12, P93
[8]   CANCER OF THE UTERINE CERVIX - SENSITIVITY AND SPECIFICITY OF SERUM SQUAMOUS-CELL CARCINOMA ANTIGEN DETERMINATIONS [J].
DUK, JM ;
DEBRUIJN, HWA ;
GROENIER, KH ;
HOLLEMA, H ;
TENHOOR, KA ;
KRANS, M ;
AALDERS, JG .
GYNECOLOGIC ONCOLOGY, 1990, 39 (02) :186-194
[9]   Biochemical prognostic factors and risk of relapses in patients with cervical cancer [J].
Gadducci, Angiolo ;
Tana, Roberta ;
Fanucchi, Antonio ;
Genazzani, Andrea Riccardo .
GYNECOLOGIC ONCOLOGY, 2007, 107 (01) :S23-S26
[10]   The diagnostic accuracy of 18F-Fluorodeoxyglucose PET/CT in patients with gynecological malignancies [J].
Grisaru, D ;
Almog, B ;
Levine, C ;
Metser, U ;
Fishman, A ;
Lerman, H ;
Lessing, JB ;
Even-Sapir, E .
GYNECOLOGIC ONCOLOGY, 2004, 94 (03) :680-684
1234